Bios Equity Partners, LP Reduces Stake in Lantern Pharma Inc. to 2.09%

Bios Equity Partners, LP has filed Amendment No. 7 to its Schedule 13D for Lantern Pharma Inc. (LTRN), reporting a decrease in its beneficial ownership. As of May 15, 2026, Bios Equity Partners, LP directly or indirectly holds 266,621 shares of common stock, representing 2.09% of the issuer's outstanding shares. This is a reduction from the 420,802 shares (3.7%) previously reported. The filing also highlights the aggregate holdings of a group of affiliated reporting persons, including Bios Fund I, Bios Fund II, and their respective general partners and controlling individuals, Aaron G.L. Fletcher and Leslie W. Kreis, Jr. Collectively, the reporting group holds 571,305 shares, or approximately 4.48% of the company. The calculation is based on a total of 12,758,872 outstanding shares. The reporting persons share voting and dispositive power over the securities through a complex structure of general partnerships and management agreements involving Bios Capital Management, LP and Bios Advisors GP, LLC.